Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) is proud to support Scientific Advancement Grants (SAG) that advance knowledge and understanding of basic, pre-clinical, outcomes and/or clinical science and to further scientific awareness and technologies for public health and welfare.
BIPI may be involved to some extent in the creation of the materials or activities (e.g. consortiums, providing suggestions or feedback) but cannot solely or disproportionately influence outcomes or hold the funding recipient accountable for achieving a specific outcome, and the funding recipient must retain ultimate control of the goals, activities, and any messaging or dissemination of knowledge.
SAGs may include third party research award programs (e.g., a professional society selected young investigator pre-clinical research grant), external research collaborations or external coalitions in which an activity or project is undertaken by BIPI along with one or more external organizations (either for-profit or not-for-profit) that advances specific and discrete shared policy or disease awareness objectives.
BIPI currently accepts SAG applications in the following Areas of Interest